296 related articles for article (PubMed ID: 22327203)
1. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
Delangle P; Mintz E
Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
[TBL] [Abstract][Full Text] [Related]
2. Design of intrahepatocyte copper(I) chelators as drug candidates for Wilson's disease.
Gateau C; Delangle P
Ann N Y Acad Sci; 2014 May; 1315():30-6. PubMed ID: 24611802
[TBL] [Abstract][Full Text] [Related]
3. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
4. Clinical considerations for an effective medical therapy in Wilson's disease.
Weiss KH; Stremmel W
Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
[TBL] [Abstract][Full Text] [Related]
5. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
Walshe JM
Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
[No Abstract] [Full Text] [Related]
6. The pattern of urinary copper excretion and its response to treatment in patients with Wilson's disease.
Walshe JM
QJM; 2011 Sep; 104(9):775-8. PubMed ID: 21622540
[TBL] [Abstract][Full Text] [Related]
7. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
8. The discovery of the therapeutic use of D-penicillamine.
Walshe JM
J Rheumatol Suppl; 1981; 7():3-8. PubMed ID: 7014875
[TBL] [Abstract][Full Text] [Related]
9. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
10. Wilson's disease.
Loudianos G; Gitlin JD
Semin Liver Dis; 2000; 20(3):353-64. PubMed ID: 11076401
[TBL] [Abstract][Full Text] [Related]
11. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
Hoogenraad TU
Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
[TBL] [Abstract][Full Text] [Related]
12. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
13. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
15. [Wilson's disease].
Kovacević I; Zekan M
Acta Med Croatica; 2003; 57(3):227-35. PubMed ID: 14582469
[TBL] [Abstract][Full Text] [Related]
16. Chelating polymeric beads as potential therapeutics for Wilson's disease.
Mattová J; Poučková P; Kučka J; Skodová M; Vetrík M; Stěpánek P; Urbánek P; Petřík M; Nový Z; Hrubý M
Eur J Pharm Sci; 2014 Oct; 62():1-7. PubMed ID: 24815561
[TBL] [Abstract][Full Text] [Related]
17. Iron accumulation in the liver of male patients with Wilson's disease.
Shiono Y; Wakusawa S; Hayashi H; Takikawa T; Yano M; Okada T; Mabuchi H; Kono S; Miyajima H
Am J Gastroenterol; 2001 Nov; 96(11):3147-51. PubMed ID: 11721763
[TBL] [Abstract][Full Text] [Related]
18. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution: the implications for Wilson's disease and arthritis therapy.
McQuaid A; Lamand M; Mason J
J Lab Clin Med; 1992 Jun; 119(6):744-50. PubMed ID: 1593220
[TBL] [Abstract][Full Text] [Related]
19. Copper chelating agents. A comparison of cupruretic responses to various tetramines and D-penicillamine.
Borthwick TR; Benson GD; Schugar HJ
J Lab Clin Med; 1980 Apr; 95(4):575-80. PubMed ID: 7359013
[TBL] [Abstract][Full Text] [Related]
20. A mechanism for the action of penicillamine in the treatment of Wilson's disease.
Peisach J; Blumberg WE
Mol Pharmacol; 1969 Mar; 5(2):200-9. PubMed ID: 4306792
[No Abstract] [Full Text] [Related]
[Next] [New Search]
